How to Buy Orchestra Biomed Holdings Stock
Orchestra Biomed Holdings Inc
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Orchestra Biomed Holdings stock last closed at $2.84, down 0.35% from the previous day, and has decreased 36.89% in one year. It has overperformed other stocks in the Biotechnology industry by 0.41 percentage points. Orchestra Biomed Holdings stock is currently +14.06% from its 52-week low of $2.49, and -67.98% from its 52-week high of $8.87.
At the moment, there are 38.31M OBIO shares outstanding. The market cap of OBIO is $108.81M. In the past 24 hours, 56,365 OBIO shares were traded.
How to Buy Orchestra Biomed Holdings Stock
Not sure how to invest in Orchestra Biomed Holdings stock? Here's how.
- Choose where to buy Orchestra Biomed Holdings stock: You need to choose an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Orchestra Biomed Holdings stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Select your payment method and add your details.
- Research Orchestra Biomed Holdings stock: The Orchestra Biomed Holdings ticker symbol is OBIO. Is Orchestra Biomed Holdings stock a good investment? Should you buy shares of OBIO? How do OBIO's underlying business fundamentals look? Do top analysts think Orchestra Biomed Holdings is a good buy? Why has OBIO's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if OBIO is a good stock to buy).
- Place your OBIO purchase: Decide if you will purchase OBIO shares at the current market price or use a limit order to buy OBIO shares at a given price.
- Get notifications regarding your OBIO investment: Create a watchlist to get the latest news on your position in Orchestra Biomed Holdings shares.
Step 1: Choose where to buy Orchestra Biomed Holdings stock
You will need a brokerage account to access the NASDAQ market and buy OBIO stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you can buy OBIO stock today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create your new brokerage account.
- Send your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've finished signing up on the best stock buying app, you need to deposit funds:
Check out this video walkthrough for more details transferring funds into your new brokerage account.
Step 4: Research Orchestra Biomed Holdings stock
After you have decided on the best place to buy Orchestra Biomed Holdings stock, it's absolutely critical to evaluate their stock before you buy, so you can understand the risk and opportunity.
Overview of key OBIO info
Orchestra Biomed Holdings Due Diligence Score
WallStreetZen was built to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on OBIO's stock page.
Is OBIO stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge OBIO's true value.
Using relative valuations metrics:
- OBIO could be undervalued based on its P/B ratio of 3.3x, relative to Biotechnology industry P/B ratio of 4.04x
You can do additional valuation analysis on OBIO's stock here.
A quick look at OBIO Financials
Signs that OBIO is financially healthy:
- There are more short-term assets than long-term liabilities on the OBIO balance sheet.
- There are more short-term assets than short-term liabilities on the OBIO balance sheet.
- OBIO has cash burn of 50847000. It has sufficient cash and short-term investments to cover this for at least one year.
Signs that OBIO is not financially healthy:
- OBIO has $66.81M in cash and short term investments. This is not enough to cover its annual cash burn of $50.85M.
- OBIO profit margin has gone down from -1,779.7% to -2,313.3% in the past year.
- OBIO has a relatively high debt to equity ratio of 1.31.
Is it a good time to buy OBIO stock, according to analysts?
Out of 4 Equities analysts who research OBIO, the consensus analyst rating on Orchestra Biomed Holdings is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Orchestra Biomed Holdings stock forecast page.
OBIO Momentum
OBIO Revenue
Last year, OBIO revenue was $2.64M. During the past four year, OBIO's revenue has increased by -17.53% per year. This was slower than the Biotechnology industry average of 44.31%.
Dive into OBIO's earnings and revenue performance here.
Are OBIO insiders buying or selling the stock?
Over the last year, insiders at OBIO have sold more shares than they have bought.
Joshua Aiello, Principal Accounting Officer of OBIO, was the latest OBIO insider to sell. They sold $1,217.64 worth of OBIO stock on Mar 26, 2025.
Dig into more about who owns OBIO shares here.
Does OBIO provide a stable income stream?
No, Orchestra Biomed Holdings doesn't provide an income stream by paying out dividends.
What others are saying about OBIO
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your OBIO purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, use a limit order.
Hit the Open button and eToro will place your order.
If you want more info about investing in stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your OBIO investment
Now that you own some OBIO stock, you'll want to stay up-to-date on your company.
Put OBIO on a watchlist to keep tabs on your OBIO stock.
OBIO Feed
How to Buy Stock in Orchestra Biomed Holdings
To summarize, here are the 6 steps for buying Orchestra Biomed Holdings stock:
- Choose where to buy Orchestra Biomed Holdings stock
- Sign up for your brokerage account
- Deposit money your investment account
- Research Orchestra Biomed Holdings stock
- Place your OBIO purchase
- Get notifications regarding your OBIO investment
If you are looking for a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep an eye on your new investment in Orchestra Biomed Holdings, create a watchlist on WallStreetZen today.
More "How To" Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.